Edition:
India

Valbiotis SA (ALVAL.PA)

ALVAL.PA on Paris Stock Exchange

2.05EUR
5 Dec 2019
Change (% chg)

€0.05 (+2.50%)
Prev Close
€2.00
Open
€2.00
Day's High
€2.10
Day's Low
€1.98
Volume
15,821
Avg. Vol
9,120
52-wk High
€4.25
52-wk Low
€1.98

Latest Key Developments (Source: Significant Developments)

Valbiotis Reports H1 Operating Loss Of 2.6 Million Euros
Friday, 30 Aug 2019 

Aug 30 (Reuters) - Valbiotis SA ::CASH POSITION OF €3.9 MILLION AT 30 JUNE 2019.H1 NET LOSS EUR 2.7 MILLION VERSUS LOSS EUR 1.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR 2.6 MILLION VERSUS LOSS EUR 1.9 MILLION YEAR AGO.H1 OPERATING REVENUE EUR 1.0 MILLION VERSUS EUR 0.5 MILLION YEAR AGO.WE APPROACH THE SECOND HALF OF THE YEAR WITH CONFIDENCE - CEO.  Full Article

Valbiotis Obtains The European Patent For VALEDIA
Monday, 11 Feb 2019 

Feb 11 (Reuters) - VALBIOTIS SAS ::VALBIOTIS OBTAINS THE EUROPEAN PATENT FOR VALEDIA®.GUARANTEED EXCLUSIVITY ON PREDIABETES AND METABOLIC DISEASES MARKET IN 38 COUNTRIES ACROSS EUROPE, INCLUDING EUROPEAN UNION.VALEDIA NOW HOLDS INDUSTRIAL PROPERTY RIGHTS FOR TWO MAJOR GLOBAL MARKETS: EUROPE AND UNITED STATES.THIS PATENT GUARANTEES EXCLUSIVE EXPLOITATION RIGHTS OF VALEDIA® UNTIL 2035 IN EUROPE, INCLUDING 28 COUNTRIES OF EUROPEAN UNION..TOTUM-63 PATENT IS CO-OWNED WITH CNRS (FRENCH NATIONAL CENTER FOR SCIENTIFIC RESEARCH).  Full Article

Valbiotis Initiates The Clinical Development Of Valediatm In The United-States With The Reverse-It Clinical Study
Tuesday, 15 May 2018 

Valbiotis SAS ::VALBIOTIS INITIATES THE CLINICAL DEVELOPMENT OF VALEDIATM IN THE UNITED-STATES WITH THE REVERSE-IT CLINICAL STUDY.  Full Article

Valbiotis Appoints Christine Roy-Duval As Director Of Development And Medical Affairs
Wednesday, 21 Mar 2018 

March 21 (Reuters) - VALBIOTIS SAS ::VALBIOTIS APPOINTS DR. CHRISTINE ROY-DUVAL AS DIRECTOR OF DEVELOPMENT AND MEDICAL AFFAIRS.  Full Article

  • Previous
  • Next

Valbiotis SA News

» More ALVAL.PA News

Earnings vs. Estimates

» More Financials